27.11.2020 • News

Solvay Sells Barium, Strontium Business to Latour

Solvay has agreed to sell its technical-grade barium and strontium business in Germany, Spain and Mexico, as well as its sodium percarbonate business In Germany to French private equity group Latour Capital. Financial terms of the deal, which is set to complete in the first quarter of 2021, were not disclosed.

The barium and strontium business includes a joint venture with Chemical Products Corp. (CPC), which is also part of the transaction.

Solvay said the divestment is a key step toward streamlining its portfolio while reducing the group’s footprint by exiting its position in niche technical-grade chemicals markets. The sale also aligns with Solvay’s G.R.O.W. strategy, aimed at driving growth, cash and returns, which was announced in November last year.

“Under Solvay’s umbrella, both businesses have established leading competitive positions and proved to have very efficient production processes,” said Didier Gaudoux, partner at Latour Capital. “We are convinced by the teams’ strong operational know-how, by the industrial sites’ operational excellence and by the intrinsic product quality. We will support the management to deliver an ambitious and sustainable growth strategy, with the right investments in capacities and continuous improvements on ESG [environmental social governance] matters.”

Author: Elaine Burridge, Freelance Journalist

Solvay has agreed to sell its technical-grade barium and strontium business in...
Solvay has agreed to sell its technical-grade barium and strontium business in Germany, Spain and Mexico, as well as its sodium percarbonate business In Germany to French private equity group Latour Capital. The deal is set to complete in the first quarter of 2021. (c) Solvay

Free Virtual Event

Batteries and Hydrogen: Competitors or Partners?
CHEManager Spotlight

Batteries and Hydrogen: Competitors or Partners?

17 September 2026 | Reserve your spot to learn where solid-state batteries and green hydrogen are headed—and how leading teams are turning them into scalable energy storage solutions.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read